NeoGenomics Inc. Files 8‑K — Regulation FD Disclosure on Settlement Press Release

What Happened

• On July 20, 2026, NeoGenomics, Inc. filed a Form 8‑K reporting a Regulation FD disclosure: the company had issued a press release on June 20, 2026 in connection with a settlement agreement described in Item 8.01 of the filing.
• The press release is attached to the 8‑K as Exhibit 99.1 (Press Release of NeoGenomics, Inc. dated July 20, 2026). The filing also includes the interactive iXBRL cover page (Exhibit 104). The report is signed by Alicia C. Olivo, Executive Vice President, General Counsel & Secretary.

Key Details

• Item 7.01: Regulation FD Disclosure — press release issued June 20, 2026 and disclosed in this 8‑K.
• Item 8.01: Other Events — references a settlement agreement (details provided in the press release/exhibit).
• Item 9.01: Exhibits — 99.1 (Press Release dated July 20, 2026) and 104 (Cover Page Interactive Data File); financial statement items (a)-(c) are listed as not applicable.
• Filing date and signature: Form 8‑K filed July 20, 2026; signed by Alicia C. Olivo.

Why It Matters

• Regulation FD disclosure means NeoGenomics publicly released information about a settlement to ensure fair access for all investors. The 8‑K links to the press release so investors can review the company’s description of the settlement.
• The 8‑K itself does not include financial statements; investors should read the attached press release (Exhibit 99.1) and monitor subsequent filings for any disclosures about financial impact or material terms of the settlement.